Risk of Chronic Kidney Disease in Bronchial Asthma

Risk of Developing Chronic Kidney Disease in Patients With Bronchial Asthma at Sohag University Hospitals

the study aims to determine the frequency and factors associated with chronic kidney disease among asthmatic patients in order to determine persons who are at risk of developing chronic kidney disease and require strict follow up in long run , to evaluate severity of asthma as a potential risk for developing kidney injury , to evaluate relationship between different inflammatory markers with severity of asthma and risk of deneloping chronic kidney disease

Study Overview

• Status: Recruiting
• Conditions: Bronchial Asthma
• Intervention / Treatment: Diagnostic test: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

Study Locations

• Egypt
  • Sohag, Egypt
    • Recruiting
    • Marihan Nazmy Shehata
    • Contact: Marihan Nazmy; Phone Number: 01224699399; Email: marihan.nazmy@med.sohag.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

cases (asthmatics) and control ( healthy ) from age of 2 years to 18 years

Description

Inclusion Criteria:

• all children diagnosed as bronchial asthma at sohag university hospitals from age of 2 years to age of 18 years and donot have any associated disease

Exclusion Criteria:

• persons who have any chronic illness persons who have any associated disease with bronchial asthma persons who missing clinical and laboratory investigations persons who refusing to give written informed consent for the study

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
cases ( asthmatic patients); asthmatics investigated by serum creatinine , GFR calculation , ESR,CRP,ABG,CBC , serum electrolytes , interleukin6, tumor necrotic factor alpha	Diagnostic test: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha; compare results of investigations in asthmatics and non asthmatics
control (healthy persons); healthy persons investigated by same investigations and compare results with asthmatics	Diagnostic test: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha; compare results of investigations in asthmatics and non asthmatics

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in kidney function in asthmatics	change in serum creatinine , GFR calculation	change in kidney function in asthmatics after diagnosis and start treatment through out the duration of study (an average 1 year )

Collaborators and Investigators

• Sponsor: Sohag University

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2024
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): July 11, 2025

Study Registration Dates

• First Submitted: June 10, 2024
• First Submitted That Met QC Criteria: June 24, 2024
• First Posted (Actual): June 25, 2024

Study Record Updates

• Last Update Posted (Actual): June 25, 2024
• Last Update Submitted That Met QC Criteria: June 24, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Urologic Diseases; Hypersensitivity, Immediate; Disease Attributes; Bronchial Diseases; Renal Insufficiency; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Asthma
• Other Study ID Numbers: soh-Med-24-05-11MS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No